In-Vitro Antiviral Screening Report

| Task Order Number: | Во9 |
|--------------------|-----|
|--------------------|-----|

| Organization: | CJSC Intelpharm |
|-----------------------|-------------------|
| Submitter Name: | Rasnetsov |
| Email: | domr_alex@mail.ru |
| Test Site: | UAB |
| Investigator: | Prichard |
| Test Date (m/dd/yy): | 6/4/13 |
| Report Date (Mmm-yy): | Jun-13 |

| Virus Screened: | Human cytomegalovirus | |
|----------------------|-----------------------|--|
| Virus Strain: | AD169 | |
| Cell Line: | HFF | |
| Vehicle: | DMSO | |
| Drug Conc. Range: | ο.096-300 μΜ | |
| Control Conc. Range: | 0.032-100 μΜ | |
| Experiment Number: | 13-cmv-018 | |

| Control Drug Name | Control Assay Order | Control Assay Name | EC50 | EC90 | CC50 | SI50 | Sigo |
|-------------------|---------------------|---|------|------|---------|------|------|
| Ganciclovir | Primary | Crystal Violet (Cytopathic effect/Toxicity) | 0.42 | 0.89 | >100.00 | >238 | >112 |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

EC50 - compound concentration that reduces viral replication by 50%

SI50 - CC50/EC50

EC90 - compound concentration that reduces viral replication by 90%

SIgo - CC50/ECgo

CC50 - compound concentration that reduces cell viability by 50%

Summary:

| Highly Active: 13-000342 | | | |
|--------------------------|--|--|--|
| 1000 | | | |
| | | | |

Screening Results

| ARB No. | Date Received m/dd/yy | Trial No | Compound Name/ID | Drug Assay Order | Drug Assay Name | EC50 | EC90 | CC50 | SI50 | Sigo |
|-----------|-----------------------------|----------|---------------------------------------|------------------|---|------|------|---------|------|------|
| 13-000342 | 5/17/13 | 1 | fullerene polyaminocaproic acid | Primary | Crystal Violet (Cytopathic effect/Toxicity) | 0.73 | 1.84 | >300.00 | >411 | >163 |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |